Volume 28, Issue 4 (Iran South Med J 2026)
Iran South Med J 2026, 28(4): 744-757 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rahimi R, Sadeghi M, Movahed A. Evaluation of the Protective Effects of Resveratrol in Reducing Inflammatory Factors after Coronary Artery Bypass Graft Surgery. Iran South Med J 2026; 28 (4) :744-757
URL: http://ismj.bpums.ac.ir/article-1-2394-en.html
URL: http://ismj.bpums.ac.ir/article-1-2394-en.html
1- Department of Biochemistry, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN
2- Department of Physiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN ,m.sadeghi@bpums.ac.ir
2- Department of Physiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, IRAN ,
Abstract: (309 Views)
Background: With its antioxidant and anti-inflammatory properties, resveratrol has significant protective effects on the heart. Despite the numerous therapeutic effects of resveratrol in traditional medicine, its anti-inflammatory effects are not conclusively approved. Therefore, the aim of this study is to investigate the protective effects of resveratrol in reducing inflammatory factors in patients after coronary artery bypass graft surgery.
Materials and Methods: The present study was conducted as a case-control study on 60 patients presenting to Bushehr Heart Center who underwent coronary artery bypass grafting. Patients were divided into a control and intervention group. The control group consisted of patients who underwent CABG surgery without receiving resveratrol, whereas the intervention group included patients who received resveratrol capsules at a dose of 250 mg twice daily, following the surgery. Resveratrol administration in the intervention group continued for 60 days from the tenth day post-surgery. At the beginning and end of the study, 10 mL of blood was collected from all patients in both groups to assess the blood levels of inflammatory factors.
Results: The results showed that the changes in serum levels of C-reactive protein, interleukin-6 and erythrocyte sedimentation rate were greater in the intervention group compared to the control group. Accordingly, the mean levels of these inflammatory factors decreased more in the intervention group than in the control group. Although the changes in white blood cell count were greater in the intervention group compared to the control group, this difference was not statistically significant.
Conclusion: Resveratrol as a strong antioxidant improved heart function and decreased inflammatory factors in the studied patients.
Materials and Methods: The present study was conducted as a case-control study on 60 patients presenting to Bushehr Heart Center who underwent coronary artery bypass grafting. Patients were divided into a control and intervention group. The control group consisted of patients who underwent CABG surgery without receiving resveratrol, whereas the intervention group included patients who received resveratrol capsules at a dose of 250 mg twice daily, following the surgery. Resveratrol administration in the intervention group continued for 60 days from the tenth day post-surgery. At the beginning and end of the study, 10 mL of blood was collected from all patients in both groups to assess the blood levels of inflammatory factors.
Results: The results showed that the changes in serum levels of C-reactive protein, interleukin-6 and erythrocyte sedimentation rate were greater in the intervention group compared to the control group. Accordingly, the mean levels of these inflammatory factors decreased more in the intervention group than in the control group. Although the changes in white blood cell count were greater in the intervention group compared to the control group, this difference was not statistically significant.
Conclusion: Resveratrol as a strong antioxidant improved heart function and decreased inflammatory factors in the studied patients.
Type of Study: Original |
Subject:
Cardiovascular System
Received: 2025/11/4 | Accepted: 2025/12/24 | Published: 2026/02/24
Received: 2025/11/4 | Accepted: 2025/12/24 | Published: 2026/02/24
References
1. Suarez A, Pulido N, Casla A, et al. Impaired tyro-sine-kinase activity of muscle insulin receptors from hypomagnesaemic rats. Diabetologia 1995; 38(11): 1262–1270. [DOI]
2. Russo M, Gurgoglione FL, Russo A, et al. Coronary artery disease and atherosclerosis in other vascular districts: epidemiology, risk factors and atherosclerotic plaque features. Life (Basel) 2025; 15(8): 1226. [DOI]
3. Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report 2018: An updated summary. J Geriatr cardiol 2020; 17(1): 1-8. [DOI]
4. Geng J, Qian J, Si W, et al. The clinical benefits of perioperative antioxidant vitamin therapy in patients undergoing cardiac surgery: a meta-analysis. Interact Cardiovasc Thorac Surg 2017; 25(6): 966–974. [DOI]
5. Mohammadi Z, Abdollahzad H, Rezaeian S, et al. The association of dietary total antioxidant capacity with inflammatory biomarkers and anthropometric indices in patients who candidate for coronary artery bypass graft surgery: a cross-sectional study. Clin Nutr Res 2021; 10(4): 353-363. [DOI]
6. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99(2): 237–242. [DOI]
7. Shaya GE, Leucker TM, Jones SR, et al. Coronary heart disease risk: low-density lipoprotein and beyond. Trends Cardiovasc Med 2022; 32(4): 181–194. [DOI]
8. Jabir NR, Firoz Ck, Kamal MA, et al. Assessment of genetic diversity in IL‐6 and RANTES promoters and their level in Saudi coronary artery disease patients. J Clin Lab Anal 2017; 31(5): e22092. [DOI]
9. Libby P. Targeting inflammatory pathways in cardiovascular disease: the inflammasome, interleukin-1, interleukin-6 and beyond. Cells 2021; 10(4): 951. [DOI]
10. Billebeau G, Vodovar N, Sadoune M, et al. Effects of a cardiac rehabilitation programme on plasma cardiac biomarkers in patients with chronic heart failure. Eur J prev cardiol 2017; 24(11): 1127-1135. [DOI]
11. Bray C, Bell LN, Liang H, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ 2016; 115(6): 317321. [Article]
12. Kawabe A, Yasu T, Morimoto T, et al. WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study. ESC heart fail 2021; 8(5): 3748–3759. [DOI]
13. Venkat R, Verma E, Daimary UD, et al. The journey of resveratrol from vineyards to clinics. Cancer Invest 2023; 41(2): 183–220. [DOI]
14. Gal R, Deres L, Horvath O, et al. Resveratrol improves heart function by moderating inflammatory processes in patients with systolic heart failure. Antioxidants 2020; 9(11): 1108. [DOI]
15. Yazdkhasti E, Purrahim Ghoroghchi A, Bahram ME. Effect of aerobic training with resveratrol supplementation on inflammatory markers and insulin resistance in women with type 2 diabetic mellitus. J North Khorasan Univ Med Sci 2021; 13(3): 70-76. (persian) [DOI]
16. Renaud S, Lorgeil M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339(8808): 1523–1526. [DOI]
17. Abe J, Yamada Y, Takeda A, et al. Cardiac progenitor cells activated by mitochondrial delivery of resveratrol enhance the survival of a doxorubicin-induced cardiomyopathy mouse model via the mitochondrial activation of a damaged myocardium. J Control Release 2018; 269: 177–188. [DOI]
18. Zhou L, Long J, Sun Y, et al. Resveratrol ameliorates atherosclerosis induced by high-fat diet and LPS in ApoE−/− mice and inhibits the activation of CD4+ T cells. Nutr Metab(Lond) 2020; 17: 41. [DOI]
19. Afshari-Safavi A, Hosseini SM, Talaei M, et al. 12-year follow-up study of the C-reactive protein in Iranian middle-aged women: Isfahan Cohort Study. Adv Hum Biol 2019; 9(2): 129 –134. [DOI]
20. Yaghobee S, Hasannia S, Hamidzadeh F, et al. Evaluation of pentraxin-3 and interleukin-6 levels in serum and gingival crevicular fluid in patients with generalized periodontitis and periodontal health controls before and after scaling and root planing. Front Dent 2025; 22: 1. [DOI]
21. Patoulias D, Stavropoulos K, Imprialos K, et al. Inflammatory markers in cardiovascular disease; lessons learned and future perspectives. Curr Vasc Pharmacol 2021; 19(3): 323–342. [DOI]
22. Tohidi M, Assadi M, Dehghani Z, et al. High sensitive C-reactive protein and ischemic heart disease, a population-based study. Iran South Med J 2012; 15(4): 253-262. (persian) [Article]
23. Nesarhosseini V, Mohammadpour RA. Relation-ship of inflammatory markers with the sintensity of coronary heart disease. J Mazandaran Univ Med Sci 2007; 16(56): 44-52. (persian) [Article]
24. Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004; 45(2): 183–193. [DOI]
25. Wainstein MV, Mossmann M, Araujo GN, et al. Elevated serum interleukin-6 is predictive of coronary artery disease in intermediate risk overweight patients referred for coronary angiography. Diabetol Metab Syndr 2017; 9: 67. [DOI]
26. Patterson CC, Smith AE, Yarnell JW, et al. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis 2010; 209(2): 551–557. [DOI]
27. Welsh C, Welsh P, Mark PB, et al. Association of total and differential leukocyte counts with cardiovascular disease and mortality in the UK Biobank. Arterioscler Thromb Vasc Biol 2018; 38(6): 1415–1423. [DOI]
28. Alende-Castro V, Alonso-Sampedro M, Fernández-Merino C, et al. C-reactive protein versus erythrocyte sedimentation rate: implications among patients with No known inflammatory conditions. J Am Board Fam Med 2021; 34(5): 974–983. [DOI]
29. Almasi J, Azizbeigi K, Mohammadzade Salamat K, et al. Effect of resveratrol supplementation during cardiac rehabilitation exercise training on inflammatory systemic factors in patients undergoing coronary artery bypass surgery: clinical trial study. J Gorgan Univ Med Sci 2020; 21(4): 14-21. (persian) [Article]
30. Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50(3): 179–187. [DOI]
31. Koushki M, Amiri Dashatan N, Meshkani R. Effect of resveratrol supplementation on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials. Clin Ther 2018; 40(7): 1180-1192. [DOI]
32. Omraninava M, Razi B, Aslani S, et al. Effect of resveratrol on inflammatory cytokines: A meta-analysis of randomized controlled trials. Eur J pharmacol 2021; 908: 174380. [DOI]
33. Diaz M, Avila A, Degens H, et al. Acute resveratrol supplementation in coronary artery disease: towards patient stratification. Scand Cardiovasc J 2020; 54(1): 14–19. [DOI]
34. Rauf A, Imran M, Suleria HAR, et al. A comprehensive review of the health perspectives of resveratrol. Food Funct 2017; 8(12): 4284–4305. [DOI]
35. Mahal HS, Mukherjee T. Scavenging of reactive oxygen radicals by resveratrol: antioxidant effect. Res Chem Intermed 2006; 32(1): 59–71. [DOI]
36. Chen Z, Xiong Q, Luo J, et al. Resveratrol nanoparticles inhibit endothelial dysfunction in abdominal aortic aneurysm by preventing eNOS uncoupling through Sirtuin 1 pathway. J Biomed Nanotechnol 2023; 19(10): 1697 1704. [DOI]
37. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch Intern Med 2005; 165(18): 2063–2068. [DOI]
38. Markó L, Vigolo E, Hinze C, et al. Tubular epithelial NF-κB activity regulates ischemic AKI. J Am Soc Nephrol 2016; 27(9): 2658–2669. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
